共 31 条
- [24] IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH MIRABEGRON ADD-ON TREATMENT IN A RANDOMIZED, DOUBLE-BLIND, PHASE 3B STUDY IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS WITH AN INADEQUATE RESPONSE TO SOLIFENACIN JOURNAL OF UROLOGY, 2016, 195 (04): : E849 - E849
- [28] Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
- [30] A TRI-ANTIGENIC HEPATITIS B VACCINE (TAV) PROVIDES CONSISTENTLY HIGHER SEROPROTECTION RATES (SPR) AND ANTI-HBS TITERS IN ALL SUBJECTS, INCLUDING THOSE KNOWN TO HAVE A REDUCED IMMUNE RESPONSE TO A MONO-ANTIGENIC VACCINE: RESULTS FROM THE PHASE 3 DOUBLE-BLIND, RANDOMIZED STUDY (PROTECT) HEPATOLOGY, 2020, 72 : 451A - 451A